Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial
Authors: Yu et al.
Posted in Papers / Original Research / Human Studies / Editor's Picks /Â May 16-31, 2023
Lancet Neurol. 2023 Jun;22(6):476-484.
PMID: 37210098 | DOI: 10.1016/S1474-4422(23)00126-6
Share this article
Sign Up For An MSC Newsletter
Become an MSC member!
Join the Migraine Science Collaborative by becoming a member! Membership gives you the opportunity to contribute to the site, and it helps build community and raise awareness of headache conditions. Visit here to sign up for free.